First-in-human phase 0 safety, imaging, pharmacokinetics, and dosimetry study of 64Cu-PD-32766, a carbonic anhydrase IX (CAIX)-targeting peptide, in patients with clear cell renal cell carcinoma ...
Priority Review and Real-Time Oncology Review aim to accelerate regulatory assessment of zanidatamab-based first-line regimens for HER2-positive advanced gastroesophageal adenocarcinoma, with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results